Ginsenoside Rb1 as an Anti-Diabetic Agent and Its Underlying Mechanism Analysis
Top Cited Papers
Open Access
- 28 February 2019
- Vol. 8 (3), 204
- https://doi.org/10.3390/cells8030204
Abstract
Panax ginseng and Panax notoginseng, two well-known medical plants with economic value, have a long history of use for managing various diseases in Asian countries. Accumulating clinical and experimental evidence suggests that notoginsenosides and ginsenosides, which are the major bioactive components of the plants, have a variety of beneficial effects on several types of disease, including metabolic, vascular, and central nervous system disease. Considerable attention has been focused on ginsenoside Rb1 derived from their common ownership as an anti-diabetic agent that can attenuate insulin resistance and various complications. Particularly, in vitro and in vivo models have suggested that ginsenoside Rb1 exerts various pharmacological effects on metabolic disorders, including attenuation of glycemia, hypertension, and hyperlipidemia, which depend on the modulation of oxidative stress, inflammatory response, autophagy, and anti-apoptosis effects. Regulation of these pathophysiological mechanisms can improve blood glucose and insulin resistance and protect against macrovascular/microvascular related complications. This review summarizes the pharmacological effects and mechanisms of action of ginsenoside Rb1 in the management of diabetes or diabetic complications. Moreover, a multi-target effect and mechanism analysis of its antidiabetic actions were performed to provide a theoretical basis for further pharmacological studies and new drug development for clinical treatment of type 2 diabetes. In conclusion, ginsenoside Rb1 exerts significant anti-obesity, anti-hyperglycemic, and anti-diabetic effects by regulating the effects of glycolipid metabolism and improving insulin and leptin sensitivities. All of these findings suggest ginsenoside Rb1 exerts protective effects on diabetes and diabetic complications by the regulation of mitochondrial energy metabolism, improving insulin resistance and alleviating the occurrence complications, which should be further explored. Hence, ginsenoside Rb1 may be developed as a potential anti-obesity, anti-hyperglycemic, and anti-diabetic agent with multi-target effects.Keywords
This publication has 110 references indexed in Scilit:
- Active ingredients of traditional Chinese medicine in the treatment of diabetes and diabetic complicationsExpert Opinion on Investigational Drugs, 2012
- The effects of ginsenoside Rb1 on JNK in oxidative injury in cardiomyocytesArchives of Pharmacal Research, 2012
- Ginsenoside Rb1 Preconditioning Enhances eNOS Expression and Attenuates Myocardial Ischemia/Reperfusion Injury in Diabetic RatsJournal of Biomedicine and Biotechnology, 2011
- Antiobesity and Antihyperglycemic Effects of Ginsenoside Rb1 in RatsDiabetes, 2010
- Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cellsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Molecular Mechanism of Insulin Resistance in Obesity and Type 2 DiabetesThe Korean Journal of Internal Medicine, 2010
- Inflammation in Diabetic Encephalopathy is Prevented by C-PeptideThe Review of Diabetic Studies, 2009
- Comparison of the pharmacological effects ofPanax ginsengandPanax quinquefoliumActa Pharmacologica Sinica, 2008
- Mechanisms linking obesity to insulin resistance and type 2 diabetesNature, 2006
- Ginsenoside Rb1 promotes adipogenesis in 3T3-L1 cells by enhancing PPARγ2 and C/EBPα gene expressionLife Sciences, 2006